Compare BAND & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | IVVD |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 437.1M |
| IPO Year | 2017 | 2021 |
| Metric | BAND | IVVD |
|---|---|---|
| Price | $16.53 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.40 | $8.75 |
| AVG Volume (30 Days) | 480.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | $53,426,000.00 |
| Revenue This Year | $17.15 | $143.48 |
| Revenue Next Year | $7.39 | $25.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 110.47 |
| 52 Week Low | $11.33 | $0.46 |
| 52 Week High | $18.63 | $3.07 |
| Indicator | BAND | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 68.06 | 51.22 |
| Support Level | $15.02 | $1.41 |
| Resistance Level | $16.64 | $2.01 |
| Average True Range (ATR) | 1.07 | 0.11 |
| MACD | 0.31 | 0.04 |
| Stochastic Oscillator | 88.30 | 87.69 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.